ALLO SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update

Nov 5, 2026

8-K

Allogene Therapeutics Announces Retirement of CFO Geoffrey Parker

Sep 2, 2026

8-K

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Aug 12, 2026

8-K

Allogene Therapeutics, Inc. Announces 2026 Annual Meeting Results and New $135 Million At-the-Market Offering

Jun 22, 2026

8-K

Allogene Therapeutics Announces CEO Transition

May 28, 2026

8-K

Allogene Therapeutics Reports Q1 2026 Financial Results and Business Update

May 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* June 2026 ATM | Offering amount: $135,000,000 | Bank: TD Cowen

Jun 22, 2026

424B5

REGISTERED OFFERING

Apr 15, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $175,000,000 | Bank: Goldman Sachs & Co. LLC

Apr 13, 2026

424B5

SHELF OFFERING | Shares amount: 37,931,035 | Share price: $2.90 | Offering amount: $110,000,001.50 | Bank: Goldman Sachs & Co. LLC

May 14, 2024

424B5

Up to $250,000,000 Common Stock PROSPECTUS SUPPLEMENT TD Cowen November 2, 2023

Nov 2, 2023

424B5

11,702,128 Shares

Jun 3, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-3

August 2026 SHELF

Aug 12, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 12, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 13, 2025

S-8

Registration

Mar 14, 2024

S-3

SHELF | ATM | Offering amount: $500,000,000.00 EFFECTIVE

Mar 14, 2024

POSASR

Up to $250,000,000 Common Stock PROSPECTUS TD Cowen March 14, 2024

Mar 14, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

Ownerships

TYPE

HEADLINE

FILED AT

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 21, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 26, 2024

CORRESP

Form CORRESP - Correspondence

Apr 23, 2024

LETTER

Form UPLOAD - SEC-generated letter

Mar 19, 2024

LETTER

Form UPLOAD - SEC-generated letter

Feb 29, 2024

CORRESP

Form CORRESP - Correspondence

Feb 22, 2024

Allogene Therapeutics, Inc. ALLO · SEC Filings